The introduction of AbbVie’s hepatitis C drugs in 2014 forced Gilead’s hand in the fight for market dominance in hepatitis C.
SHELTON, CONNECTICUT / ACCESS Newswire / November 10, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) today reported that it has received approval to Start Phase II Clinical Trial of ...
Enanta Pharmaceuticals recorded a narrower loss as sales rose in its fiscal fourth quarter driven by higher sales of a hepatitis C virus treatment.
Health and Me on MSN
Can Catching The Flu Or COVID-19 Sharply Raise Your Heart Risk?
A major review shows flu and COVID-19 infections can sharply raise short-term risks of heart attacks and strokes, with ...
Scientists have recently conducted a meta-analysis of over 150 research studies, and determined that infections with viruses ...
The ECDC says the region could still meet its testing targets for HIV, but that it will be harder to improve detection for ...
Among a large cohort of U.S. veterans, those with chronic hepatitis C virus infection had an increased risk of pancreatic cancer versus those with no infection. Exposure to hepatitis C virus infection ...
NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum ...
To make hepatitis testing more accessible, the Pocatello Free Clinic is administering free hepatitis tests at various locations from Tuesday through Thursday.
The report card is mixed. Thanks to the efforts of community-based health organizations, researchers and healthcare providers ...
The report card is mixed. Thanks to the efforts of community-based health organizations, researchers and healthcare providers ...
Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) Q3 2025 Earnings Call Transcript November 12, 2025 Atea Pharmaceuticals, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback